Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.64 |
| ▸ | CA2 | P00918 | 3/20 | 0.64 |
| ▸ | CA1 | P00915 | 2/20 | 0.64 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | RECQL | P46063 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | CASP1 | P29466 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 2/20 | 0.52 |
| ▸ | TGM2 | P21980 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28024787 | 0.98 | CA12 (0.61) | CA12CA2CA1ENPP2ALDH1A1 | |
| SCHEMBL16965230 | 0.93 | CA12 (0.57) | CA12CA2CA1ENPP2ALDH1A1 | |
| SCHEMBL27611963 | 0.84 | CA12 (0.48) | CA12CA2CA1ENPP2ALDH1A1 | |
| SCHEMBL25667539 | 0.82 | ENPP2 (0.54) | CA12CA2CA1ENPP2CA9 | |
| SCHEMBL8418962 | 0.82 | CA12 (0.67) | CA12CA2CA1ALDH1A1RECQL | |
| SCHEMBL6807008 | 0.81 | ENPP2 (0.48) | CA12CA2CA1ENPP2ALDH1A1 | |
| SCHEMBL2376239 | 0.81 | ENPP2 (0.72) | ENPP2PTGS2 | |
| Hydrochloric Acid SCHEMBL6511659 | 0.79 | ENPP2 (0.46) | CA12CA2CA1ENPP2ALDH1A1 | |
| SCHEMBL25511708 | 0.79 | CA12 (0.56) | CA12CA2CA1ALDH1A1RECQL | |
| SCHEMBL23129682 | 0.78 | ENPP2 (0.50) | CA12CA2CA1ENPP2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024196936-A2 | LOCALIZED HIGH CONCENTRATION ELECTROLYTE AND LITHIUM-ION BATTERY COMPRISING THE SAME | SILA NANOTECHNOLOGIES, INC. (US) | 2024-09-26 | — | — | WO | claimed |
| US-20240322244-A1 | LOCALIZED HIGH CONCENTRATION ELECTROLYTE AND LITHIUM-ION BATTERY COMPRISING THE SAME | SILA NANOTECHNOLOGIES, INC. | 2024-09-26 | — | — | US | claimed |
| CN-110669058-A | Tricyclic quinolone carboxylic acid and preparation method thereof | 江西农业大学 | 2020-01-10 | — | — | CN | claimed |
| CN-107205391-A | Histone demethylase inhibitors | 赛尔基因昆蒂赛尔研究公司 | 2017-09-26 | — | — | CN | claimed |
| US-8367667-B2 | Pyrrole derivatives as pharmaceutical agents | EXELIXIS, INC. (US) | 2013-02-05 | — | — | US | claimed |
| CN-102617578-A | Imidazole derivative and medicine application thereof | HUTCHISON WHAMPOA SHANGHAI LTD | 2012-08-01 | — | — | CN | claimed |
| US-20110301128-A1 | Pyrrole Derivatives As Pharmaceutical Agents | EXELIXIS, INC. (US) | 2011-12-08 | — | — | US | claimed |
| CN-101423518-A | Imidazole derivative and medical application thereof | HUTCHISON MEDIPHARMA SHANGHAI (CN) | 2009-05-06 | — | — | CN | claimed |
| US-20080234270-A1 | Pyrrole Derivatives As Pharmaceutical Agents | EXELIXIS, INC. (US) | 2008-09-25 | — | — | US | claimed |
| EP-1773768-A4 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2008-08-06 | — | — | EP | claimed |
| EP-1773768-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| WO-2006012642-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2006-02-02 | — | — | WO | claimed |
| WO-2024196936-A2 | LOCALIZED HIGH CONCENTRATION ELECTROLYTE AND LITHIUM-ION BATTERY COMPRISING THE SAME | SILA NANOTECHNOLOGIES, INC. (US) | 2024-09-26 | — | — | WO | disclosed |
| US-20240322244-A1 | LOCALIZED HIGH CONCENTRATION ELECTROLYTE AND LITHIUM-ION BATTERY COMPRISING THE SAME | SILA NANOTECHNOLOGIES, INC. | 2024-09-26 | — | — | US | disclosed |
| WO-2023159307-A9 | POLO-LIKE KINASE 4 (PLK4) INHIBITORS, PHARMACEUTICAL COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF | REPARE THERAPEUTICS INC. (CA) | 2024-03-21 | — | — | WO | disclosed |
| CN-117396471-A | Novel piperidine derivatives and pharmaceutical compositions for inhibiting autotaxin comprising the same | 株式会社次代生物科学 | 2024-01-12 | — | — | CN | disclosed |
| WO-2005056004-A1 | N-ALKYL PYRROLES AS HMG-COA REDUCTASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2005-06-23 | — | — | WO | disclosed |
| EP-1487824-A1 | DIAMINO-PYRIMIDINES AND THEIR USE AS ANGIOGENESIS INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003074515-A1 | DIAMINO-PYRIMIDINES AND THEIR USE AS ANGIOGENESIS INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-09-12 | — | — | WO | disclosed |
| CN-1278794-A | Substituted 2-hydroxyindole derivatives as inhibitors of protein tyrosine kinases and protein serine/threonine kinases | GLAXO GROUP LTD (GB) | 2001-01-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301128-A1 | Pyrrole Derivatives As Pharmaceutical Agents | PRLHR, PTGDR, TACR1 | CA12 3901/4885CA2 1737/4885CA1 2327/4885 |
| US-20080234270-A1 | Pyrrole Derivatives As Pharmaceutical Agents | PRLHR, PTGDR, TACR1 | CA12 3901/4885CA2 1737/4885CA1 2327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.